Non-pegylated long-circulating liposomes
First Claim
Patent Images
1. A process for manufacture of long circulating non-pegylated liposomes comprising;
- forming a lipid film by evaporating a solvent from a lipid solution comprising one or more phospholipids, a sterol and a solvent;
hydrating the lipid film with an aqueous hydration media to form non pegylated liposomes;
wherein the amount of aqueous hydration media used is in the range of 10 to 35 ml for each mmole of phospholipid present in the lipid solution.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.
45 Citations
60 Claims
-
1. A process for manufacture of long circulating non-pegylated liposomes comprising;
-
forming a lipid film by evaporating a solvent from a lipid solution comprising one or more phospholipids, a sterol and a solvent;
hydrating the lipid film with an aqueous hydration media to form non pegylated liposomes;
wherein the amount of aqueous hydration media used is in the range of 10 to 35 ml for each mmole of phospholipid present in the lipid solution. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
23. A long circulating non-pegylated liposomal doxorubicin composition for parenteral administration comprising, doxorubicin hydrochloride non-pegylated liposomes, histidine hydrochloride, and sucrose;
-
wherein the doxorubicin non-pegylated liposomes comprise distearoylphosphatidyl choline, cholesterol, sucrose;
wherein the liposomes have an average size 0.06 μ
m to 0.16 μ
m; and
wherein the non-pegylated doxorubicin liposomes have a circulation time in blood at least 25 times longer than that of ADRIAMYCIN when tested in Swiss albino mice at equivalent doses. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)
-
-
43. A process for manufacture of a long circulating non-pegylated liposomal doxorubicin composition for parenteral administration comprising
(j) dissolving lipids comprising Distearoylphosphatidylcholine (DSPC) and cholesterol in a single solvent or in a mixture of solvents, (k) removing said solvents before or after hydrating the lipids by addition of an aqueous hydration media to form liposomes in a liposomal composition, wherein said aqueous hydration media comprises ammonium sulfate and sucrose, and wherein the aqueous hydration media is added in quantities in the range of 10 ml to 35 ml per each mmole of DSPC; -
(l) sizing the liposomes in the liposomal composition obtained at the end of step (b), to about 0.060 μ
m-0.16 μ
m;
(m) removing extraliposomal ammonium sulfate from the liposomal composition that has undergone sizing at step (c), using a sucrose-histidine buffer solution comprising histidine hydrochloride and sucrose;
(n) dissolving doxorubicin hydrochloride in said sucrose-histidine buffer solution to obtain a solution of at least 25mM doxorubicin hydrochloride concentration;
(o) admixing doxorubicin hydrochloride solution obtained at step (e) and the liposomal composition obtained at the end of step (d) to obtain doxorubicin hydrochloride loaded liposomal composition;
(p) removing extraliposomal doxorubicin hydrochloride from the liposomal composition by a process selected from the group consisting of tangential flow filtration, column chromatography and treatment with resins;
(q) making up the volume of the liposomal composition obtained at the end of step (g) with said sucrose-histidine buffer solution to obtain a liposomal composition of a desired concentration of doxorubicin hydrochloride;
(r) filtering aseptically, the liposomal composition through a sterile 0.2μ
sterilising grade filter into a sterile container to obtain said liposomal doxorubicin composition. - View Dependent Claims (44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)
-
-
60. A process for manufacture of long circulating non-pegylated sized liposomes comprising;
-
dissolving one or more phospholipids, and a sterol in a solvent or mixture of solvents;
removing said solvents before after hydrating the phospholipids by addition of a aqueous hydration media to form non-pegylated liposomes;
wherein the amount of the aqueous hydration media used is in the range of 10 to 35 ml for each mmole of phospholipid present in the lipid solution;
sizing the non-pegylated liposomes to about 0.06 μ
m to 0.1 μ
m to form a liposomal composition;
removing extra-liposomal hydration salt from the liposomal composition using sucrose-histidine buffer solution to form non-pegylated sized liposomes.
-
Specification